Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 6/20 | 0.47 |
| ▸ | WRN | Q14191 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568757 | 0.92 | BLM (0.56) | BLMWRNHSD17B10MEN1HPGD | |
| SCHEMBL21568276 | 0.92 | BLM (0.56) | BLMWRNHSD17B10MEN1HPGD | |
| SCHEMBL23256590 | 0.90 | KCNQ3 (0.46) | BLMWRNHSD17B10MEN1HPGD | |
| SCHEMBL21568229 | 0.90 | BLM (0.54) | BLMWRNHSD17B10MEN1HPGD | |
| SCHEMBL21568374 | 0.90 | BLM (0.54) | BLMWRNHSD17B10MEN1HPGD | |
| SCHEMBL23256591 | 0.88 | BLM (0.56) | BLMHSD17B10 | |
| SCHEMBL23256876 | 0.85 | MAPT (0.53) | BLMHSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23256888 | 0.83 | NSD2 (0.53) | BLMHSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21569108 | 0.82 | KDM4E (0.56) | HSD17B10MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL21569167 | 0.81 | CXCR2 (0.50) | BLMHSD17B10MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | BLM 619/4885WRN 1572/4885HSD17B10 4412/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | BLM 692/4885WRN 1892/4885HSD17B10 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.